NCT02718469 - Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2015

Primary Completion Date

September 15, 2016

Study Completion Date

September 15, 2016

Conditions

Ebola Virus Disease

Interventions

BIOLOGICAL

Ebola Vaccine - low dose

2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Ebola Vaccine - mid dose

2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Ebola Vaccine - high dose

2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28

BIOLOGICAL

Placebo

2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort

Trial Locations (1)

Optimal Research, Melbourne